Spironolactone in Alcohol Use Disorder (SAUD)

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions
Alcohol Use Disorder
Interventions
OTHER

Placebo

Placebo

DRUG

Spironolactone

"Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information."

Trial Locations (1)

21224

RECRUITING

National Institute on Drug Abuse, Baltimore

All Listed Sponsors
lead

National Institute on Drug Abuse (NIDA)

NIH